NCT02989350

Efficacy of Lactobacillus Reuteri DSM 17938 for the Treatment of Acute Gastroenteritis in Children

Efficacy of Lactobacillus Reuteri DSM 17938 for the Treatment of Acute Gastroenteritis in Children: Randomised Controlled Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Szpital im. Św. Jadwigi Śląskiej · Academic / Other
• Sex: All
• Age: 2 Months – 60 Months
• Healthy volunteers: Not accepted

Summary

Acute gastroenteritis (AGE) is one of the most common diseases among children. Oral rehydration therapy is the key treatment. According to the 2014 guidelines developed by the ESPGHAN probiotics may be considered in the management of children with AGE in addition to rehydration therapy. Considering that evidence on L reuteri remains limited, the investigators aim to assess the efficacy of L reuteri DSM 17938 for the treatment of AGE in children. Children vaccinated and not vaccinated against rotavirus will be evaluated separately. Two independent reports (rotavirus-vaccinated and non-vaccinated children) are planned.

Conditions

• Acute Gastroenteritis

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Lactobacillus reuteri DSM 17938	Lactobacillus reuteri DSM 17938 vs Placebo
DIETARY_SUPPLEMENT	Placebo	Lactobacillus reuteri DSM 17938 vs Placebo

Timeline

• Start date: 2017-01-16
• Primary completion: 2018-11-01
• Completion: 2018-11-01
• First posted: 2016-12-12
• Last updated: 2019-01-30

Locations

1 site across 1 country: Poland